←
Leman Mutlu1,137 posts
Leman Mutlu avatar

Leman Mutlu

@LemMutlu

Immunology/Allergy Consultant , proud to work in the NHS, fascinated by complex PID and most things Allergy and Immunology, Rhodopean, opinions my own

◷ Joined November 2021▧ 43 Photos and videos
Allergy EAACI avatar
⟳ Leman Mutlu retweeted
Allergy EAACI@AllergyEaaci·Sep 16

#Respiratory #inflammation spans a spectrum of upper and lower airway diseases, asthma, chronic rhinosinusitis, allergic and non-allergic rhinitis, and COPD, unified by overlapping type 2 and non-type 2 inflammatory mechanisms. Biologic and small-molecule therapies targeting IL-4/IL-13, IL-5, IgE, and corticosteroid-responsive pathways have reshaped management across these conditions, shifting the therapeutic aim from symptom control toward sustained remission. Substantial heterogeneity nonetheless persists in inflammatory endotype, airway remodeling, and treatment response. This complexity is driving growing interest in transcriptomic, metabolomic, and cellular signatures capable of endotyping respiratory inflammation across the airways. In this issue, Roth-Walter et al. present a EAACI position paper discussing small-molecule drugs and RNA-based therapeutics as an emerging complement to biologics in precision medicine for chronic inflammatory diseases. Scheire and Lourijsen et al. present an EAACI Task Force meta-analysis showing that cumulative systemic glucocorticosteroid doses between 500 mg and 1 g prednisolone-equivalent significantly raise the risk of adverse effects in patients with upper airway disease and asthma. Gunaydin et al. review the evidence and predictors behind asthma remission as an achievable treatment goal. Nguyen et al. discuss the growing use of artificial intelligence in allergy, asthma, and immunology, including its association with environmental exposure data. Virchow and Bertels et al. present a EUFOREA consensus aiming to establish practical guidance for inducing and maintaining remission in global airway disease. Gangemi and Manti et al. present an operational landscape that integrates cellular remodeling pathways, structural readouts, and digital biomarkers with advanced AI to drive disease modification in severe asthma. Matsuyama et al. show that IL-33, together with oxidised low-density lipoprotein and complement fragments, drives inflammatory extracellular trap formation in eosinophils. Kumar and Chan et al. link small airways dysfunction to reduced rates of asthma remission. Wen et al. demonstrate that seven genes and two Weighted Gene Co-Expression Network Analysis (WGCNA) modules are consistently elevated in asthma across both the lower and upper airways. Andersson et al. find significant associations in BMI, sex and steroid treatment on circulating adipokine levels, highlighting the complexity of mechanisms underlying obesity-related asthma and adipose-related adipokine dysregulation. Pathinayake et al. show that resolving endoplasmic reticulum protein misfolding restores corticosteroid sensitivity in experimental models of severe, steroid-resistant asthma. Cannata et al. reveal that MAIT cells suppress IgE-mediated asthma through an IFNγ-dependent regulation of B cells. Pyung and Kang et al. identify three metabolite-defined subgroups of clinically stable asthma with distinct lung function, airway structure, and immune profiles. Wechsler et al. report that dupilumab reduces circulating type 2 biomarkers and improves lung function in persistent asthma. Song and Kermani et al. examine the role of cellular senescence in severe asthma. Yang and Seo et al. find that longer asthma duration is associated with elevated non-type 2 sputum biomarkers and reduced type 2 inflammation in severe asthma. Shen et al. define distinct airway transcriptomic endotypes in type 2 biomarker-high and -low severe asthma, independent of corticosteroid effects. Chae and An et al. identify four plasma metabolomic subgroups of adult asthma with distinct clinical and lipid-metabolism profiles. Declercq et al. establish chitin as a potent adjuvant for type 2 airway inflammation, independent of endogenous chitinolytic activity. ...continued in the comments journalallergy.com

Post attachment
RC of Pathologists avatar
⟳ Leman Mutlu retweeted
RC of Pathologists@RCPath·Aug 28

Join the 1st webinar in our World Patient Safety Day series on 1 September. Hear expert insights on point-of-care testing, emerging technologies and best practice. Plus, earn 1 self-accredited CPD point. Register free: ow.ly/GKr950ZFyiw #POCT #RCPathWPSD

Post attachmentPost attachment
BSI Clinical Immunology Professional Network avatar
⟳ Leman Mutlu retweeted
BSI Clinical Immunology Professional Network@BSI_CIPN·Jul 22

How do the best research questions arise? Dr Fatima Dhalla discusses why clinical immunologists are uniquely placed to identify the questions that matter most to patients, and how research can complement a clinical career. Watch the full interview: vist.ly/5c3uy

0:51
EAACI avatar
⟳ Leman Mutlu retweeted
EAACI@EAACI_HQ·Jul 3

How does IL-25 contribute to epithelial barrier dysfunction in chronic rhinosinusitis with nasal polyps (CRSwNP)? In a new study, Baodan Zhang and colleagues investigated the molecular mechanisms by which IL-25 affects the nasal epithelial barrier. The authors report that: • IL-25 is expressed in nasal epithelial cells and signals through IL-17Rh1. • IL-25 stimulation disrupts epithelial tight junctions, resulting in reduced ZO-1 expression. • This effect is mediated through Act1-dependent activation of the NF-κB and MAPK signalling pathways. These findings advance our understanding of epithelial barrier dysfunction in CRSwNP and provide further insights into the role of IL-25 in upper airway inflammation. Read the full article: onlinelibrary.wiley.com/doi/… #CTAJournal #EAACI #CRSwNP #Inflammation #EpithelialBarrier #IL25 #Rhinosinusitis #AllergyResearch #Immunology #TranslationalResearch

Post attachment
BSACI avatar
⟳ Leman Mutlu retweeted
BSACI@BSACI_Allergy·Jul 2

Congratulations to Runa Ali, Ricardo Madrigal and the Allergy and Severe Asthma team at @NHSBartsHealth on achieving Royal College of Physicians IQAS accreditation, as well as being recognised as a World Allergy Organization Centre of Excellence.

Post attachment
ID:IOTS podcasting / idiots-pod.bsky.social avatar
⟳ Leman Mutlu retweeted
ID:IOTS podcasting / idiots-pod.bsky.social@IDiots_pod·Jun 20

I vote give everyone Cefazolin for 5 days then oral switch and forget about it. Benpen 6x/d pisses off the nurses, Fluclox makes people’s kidneys explode and Cefazolin does neither of those things. It’s only pricey compared to Fcx/benpen after all

EAACI avatar
⟳ Leman Mutlu retweeted
EAACI@EAACI_HQ·Jun 19

🏆 Celebrating Excellence at EAACI Congress 2026 Behind every scientific breakthrough, every clinical advancement and every step forward in patient care are dedicated individuals working to improve lives. During EAACI Congress 2026, we were proud to recognise outstanding clinicians, researchers, educators and emerging talents whose contributions continue to shape the future of allergy, asthma and clinical immunology. Their achievements reflect the passion, innovation and collaboration that drive our global community forward and bring us closer to a future free from the burden of allergic and immunological diseases. Congratulations to all EAACI Award recipients, Fellows and Knowledge Exam awardees recognised this year. Read the full story and discover the 2026 honourees: 🔗 eaaci.org/news/eaaci-celebra… #EAACI2026 #EAACI #ScientificExcellence #Allergy #Immunology #Research #Healthcare #MedicalEducationz

Post attachmentPost attachmentPost attachmentPost attachment
EAACI avatar
⟳ Leman Mutlu retweeted
EAACI@EAACI_HQ·Jun 15

🎥 Day 3 in 60 seconds. Innovation. Exchange. Progress. EAACI Congress 2026 continued in Istanbul with another inspiring day of scientific discovery, meaningful conversations, and global collaboration. From groundbreaking discussions on precision medicine and targeted therapies to thought-provoking talks, leadership engagement, and patient-centred perspectives, Day 3 highlighted the ideas and partnerships shaping the future of allergy and clinical immunology. Watch the highlights and experience the momentum of #EAACICongress2026. ✨ 🌍 Vision Zero: A Future Free from Allergy and Asthma Burden. #EAACI #Allergy #Asthma #ClinicalImmunology #Immunology #MedicalCongress #Healthcare #Research #Istanbul

0:59
Jeffrey Modell Foundation (JMF) avatar
⟳ Leman Mutlu retweeted
Jeffrey Modell Foundation (JMF)@Info4PI·May 19

Honoring excellence in immunology 🧬✨ We were proud to present the 2025 Jeffrey Modell Prize to Dr. Patricia Rodriguez Morales, standing alongside Harvard Immunology Graduate Committee program directors Dr. Shiv Pillai and Dr. Wendy Garrett. This award celebrates a graduating PhD student whose research is advancing the future of immunology. The evening also featured opening remarks from Dr. Fred Alt, representing the Jeffrey Modell Foundation at this special annual event at Harvard Medical School. Here’s to the researchers, mentors, and leaders driving progress forward. 💙 #Immunology #MedicalResearch #JeffreyModellFoundation #PIAwareness #FutureOfMedicine #HarvardMedicalSchool

Post attachmentPost attachment